Dr. Septien joins Bionure at a crucial time, as the company is preparing for a phase 2 clinical study with its lead compound, BN201. Her wealth of experience in drug development and regulatory challenges will help the company finalize and deploy its clinical development plan and regulatory strategy and execute the upcoming phase 2 program.

Prior to joining Bionure, Dr. Septien worked as a clinical doctor in neurology and psychiatry then held senior medical and regulatory roles with a focus on neuroscience at major pharmaceutical companies, including Pfizer, Wyeth, GSK, Servier and Ipsen. She later moved to the biotech sector as chief medical officer at DBV Technologies.